安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- News - Reven Pharmaceuticals
Recent Reven Pharma press releases and other news in the pharma industry, including broad medical treatment news and current issues
- Reven Pharmaceuticals Response - Reven hits back, opposing SEC’s . . .
In early 2020, the COVID-19 pandemic disrupted many of Reven’s plans, yet Reven continued to make progress toward its goals, including by engaging Jeff Halverson as its CFO and tasking him with helping complete tax returns for Reven and its related entities in preparation for an audit
- Overview - Reven Pharmaceuticals
Reven is dedicated to investigating neglected diseases with unmet therapeutic needs and areas of medicine where current standard of care is often not successful Our goal is to deliver innovative medicines based on the RJX technology to patients in need
- REVEN ANNOUNCES A STRATEGIC LICENSING PARTNERSHIP WITH ENLIGHTENED . . .
reven announces a strategic licensing partnership with enlightened nutraceutical solutions, llc (ens) to allow ens to leverage reven’s clinical research in anti-inflammatory and antioxidant medicine toward its efforts to develop new proprietory vitamin and nutrient based products
- Reven Holdings Announces Successful Completion of the First Part of . . .
Reven today announced the successful completion of Part 1 of the Two-Part, Two Cohort Multi-Center Phase I II trial of Reven’s lead anti-sepsis drug candidate RJX in hospitalized high-risk COVID-19 patients
- Reven Announces New Chief Operating Officer
Reven is pleased to announce the appointment of Daniel Hoffman as Chief Operating Officer, effective immediately Mr Hoffman will support co-founders Peter Lange, Michael Volk, and Brian Denomme in executing their vision in bringing the company's flagship platform drug Rejuveinix (RJX) to market
- Products - Reven Pharmaceuticals
Reven LLC 2205 W 136 Ave 106218 Broomfield, CO 80023 1-866-REVEN-RX (1-866-738-3679)
- Social Accountability - Reven Pharmaceuticals
At Reven, we believe that good medicine strives to serve ALL patients with better outcomes and affordable solutions Our vision is to reduce patient cost by striving to deliver definitive outcomes with multi-modal treatments, instead of single-mode therapies that only delay disease progression
|
|
|